Medicus Pharma Ltd., a biotech/life sciences company, focuses on accelerating the clinical development programs of novel and disruptive therapeutic assets. It develops SkinJect, with an indication for basal cell carcinoma that is drug device combination product using novel dissolvable microneedle arrays for the treatment of non-melanoma skin cancers. The company was founded in 2015 and is headquartered in Toronto, Canada.
